Bill
HR 8205
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
119th Congress
Introduced by Robert Aderholt and 70 co-sponsors
HR 8205 extends federal ALS treatment acceleration programs through 2031, maintaining expedited FDA review processes and research funding for amyotrophic lateral sclerosis therapies.
Committee Consideration and Mark-up Session Held